Get started
Author

Carolyn P. Evan

Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer
2018 · Anis A. Hamid, Kathryn P. Gray, et al. · European Urology · 270
Elevated IL‐8, TNF‐α, and MCP‐1 in men with metastatic prostate cancer starting androgen‐deprivation therapy (ADT) are associated with shorter time to castration‐resistance and overall survival
2014 · Jaya Sharma, Kathryn P. Gray, et al. · The Prostate · 84
Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease
2015 · Che-kai Tsao, Kathryn P. Gray, et al. · The Journal of Urology · 73
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry
2019 · Edoardo Francini, Kathryn P. Gray, et al. · Prostate Cancer and Prostatic Diseases · 72
Development of an Integrated Prostate Cancer Research Information System
2006 · William K. Oh, Julia Hayes, et al. · Clinical Genitourinary Cancer · 67
Association of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancer–Specific Mortality
2011 · Mark M. Pomerantz, Lillian Werner, et al. · Cancer Prevention Research · 48
The risk of renal impairment in hormone‐refractory prostate cancer patients with bone metastases treated with zoledronic acid
2007 · William K. Oh, Kevin Proctor, et al. · Cancer · 46
PDF
Elevated insulin‐like growth factor binding protein‐1 (IGFBP‐1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival
2013 · Jaya Sharma, Kathryn P. Gray, et al. · The Prostate · 45
Association between CD8 and PD‐L1 expression and outcomes after radical prostatectomy for localized prostate cancer
2020 · Cecile Vicier, Praful Ravi, et al. · The Prostate · 35
Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer
2017 · Edoardo Francini, Steven Yip, et al. · Clinical Genitourinary Cancer · 18
PDF
Role of Androgen Deprivation Therapy in Early Salvage Radiation Among Patients With Prostate-Specific Antigen Level of 0.5 or Less
2014 · Arti Parekh, Ming-Hui Chen, et al. · Clinical Genitourinary Cancer · 18
Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center
2015 · Vinayak Muralidhar, Meredith M. Regan, et al. · Clinical Genitourinary Cancer · 12
Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases
2020 · Bradley McGregor, Li Zhang, et al. · Prostate Cancer and Prostatic Diseases · 10
PDF
Immune infiltrate with CD8 low or PDL1 high associated with metastatic prostate cancer after radical prostatectomy (RP).
2019 · Cecile Vicier, Lillian Werner, et al. · Journal of Clinical Oncology · 7
Characterization of patients who present with de novo metastatic prostate cancer: Single-institution database analysis.
2013 · Jessica Strock, Kathryn P. Gray, et al. · Journal of Clinical Oncology · 5
Co4 a Comparison of Logistic Regression and Cox Proportional Hazards Models for Identification of Risk Factors for Renal Impairment in Hormone Refractory Prostate Cancer (hrpc) Patients With Bone Metastases (bm) Treated With Zoledronic Acid (za)
2005 · WK Oh, K Proctor, et al. · Value in Health · 5
Outcomes of prechemotherapy (pCRx) abiraterone acetate (AA) or enzalutamide (E) for metastatic castration-resistant prostate cancer (mCRPC) after ADT + Docetaxel (D) or ADT alone for metastatic hormone sensitive prostate cancer (mHSPC) in a multi-institution hospital-based registry
2017 · E. Francini, S. Yip, et al. · Annals of Oncology · 3
PDF
Impact of new systemic therapies on outcomes of patients with non-metastatic castration resistant prostate cancer (nmCRPC).
2019 · Cecile Vicier, Wanling Xie, et al. · Journal of Clinical Oncology · 2
Impact of new systemic therapies on overall survival (OS) of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) in a hospital-based registry.
2018 · Edoardo Francini, Kathryn P. Gray, et al. · Journal of Clinical Oncology · 2
Bone targeted therapy and skeletal related events in the era of modern therapies for castration resistant prostate cancer with bone metastases.
2018 · Li Zhang, Kathryn P. Gray, et al. · Journal of Clinical Oncology · 1
Duration of androgen deprivation therapy for high-risk prostate cancer: Application of randomized trial data in a tertiary referral cancer center.
2016 · Vinayak Muralidhar, Meredith M. Regan, et al. · Journal of Clinical Oncology · 1
Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer (AIPC)
2005 · M. Nakabayashi, M. M. Regan, et al. · Journal of Clinical Oncology · 1
Supplementary Table S5 from Association of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancer–Specific Mortality
2023 · Mark M. Pomerantz, Lillian Werner, et al.
PDF
Supplementary Table S1 from Association of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancer–Specific Mortality
2023 · Mark M. Pomerantz, Lillian Werner, et al.
Supplementary Table S3 from Association of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancer–Specific Mortality
2023 · Mark M. Pomerantz, Lillian Werner, et al.
Works count: 40
Citation count: 825
H-index: 12
I10-index: 13
Year
Topic
Type